TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11240980

Group type: EXPERIMENTAL
Intervention: Triple therapy with 20 mg of omeprazole or 30 mg of lansoprazole twice a day, 200 mg of clarithromycin three times a day, and 500 mg of amoxicillin three times a day for 1 week
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Dual high-dose lansoprazole (30 mg four times daily) and amoxicillin (500 mg four times daily) for 2 weeks
Number of subjects: 261

Group type: COMPARATOR
Intervention: Initial treatment with triple therapy
Number of subjects: 261
Study: 9772054

Group type: EXPERIMENTAL
Intervention: RCM (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Metronidazole 400 mg b.d.)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RAC (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Clarithromycin 500 mg b.d.)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RAM (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Metronidazole 400 mg b.d.)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RC (Rabeprazole 20 mg b.d., Clarithromycin 500 mg b.d.)
Number of subjects: 75
Study: 8145782

Group type: EXPERIMENTAL
Intervention: Dietary intervention group (20% of total caloric intake as fat)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 76
Study: 3344944

Group type: EXPERIMENTAL
Intervention: oesophageal detector device
Number of subjects: 100
Study: 1361746

Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg), subcutaneously, three times a week for 24 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo, subcutaneously, three times a week for 24 weeks
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg), subcutaneously, three times a week for 52 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo, subcutaneously, three times a week for 52 weeks
Number of subjects: 91
Study: 70119

Group type: EXPERIMENTAL
Intervention: CT myelography
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional myelography
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Concentric compression of the cord in a narrow canal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nerve-root swelling
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Disk herniation with occlusion of the corresponding foramen
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: No abnormalities in cord and nerve roots
Number of subjects: 80
Study: 31086071

Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) promoting ACW with social and behavioral strategies
Number of subjects: 2649

Group type: COMPARATOR
Intervention: Comparison group (COM) participating only in data collection
Number of subjects: 2649
Study: 28475670

Group type: EXPERIMENTAL
Intervention: Mechanically washed allogenic RBCs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care RBCs
Number of subjects: 60
Study: 25547113

Group type: EXPERIMENTAL
Intervention: Training package including usual postgraduate course, additional training days, outreach visits, regional meetings, and access to a reporting system for occupational therapists.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Postgraduate course for occupational therapists only (Control).
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Training package (Experimental Intervention).
Number of subjects: 71
Study: 23396736

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) added to pegylated interferon-alpha-2a and ribavirin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pegylated interferon-alpha-2a and ribavirin (control group)
Number of subjects: 72
Study: 21289606

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19827277

Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (usual conservative treatment: NSAIDs, local splinting, local heat)
Number of subjects: 51
Study: 17094417

Group type: EXPERIMENTAL
Intervention: FP (5-FU 800 mg/m2/d in continuous infusion for 5 days and cisplatin 100 mg/m2 on day 1 or 2)
Number of subjects: 232

Group type: COMPARATOR
Intervention: FLP (LV 100 mg/m2/d in bolus for 5 days, followed by 5-FU 350 mg/m2/d in 1 h infusion for 5 days and cisplatin 100 mg/m2 on day 1 or 2)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: FP
Number of subjects: 232

Group type: COMPARATOR
Intervention: FLP
Number of subjects: 232
Study: 15754082

Group type: EXPERIMENTAL
Intervention: Lower extremity training using weight belts (mean 7.8 kg) in step-ups and chair rises
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Upper extremity training using elastic bands and dumbbells
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both groups (lower and upper extremity training)
Number of subjects: 189
Study: 11153737

Group type: EXPERIMENTAL
Intervention: Invasive management strategy (routine early coronary angiography)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conservative management strategy (noninvasive functional assessment)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Invasive management strategy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conservative management strategy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Overall event rates (death or recurrent nonfatal MI)
Number of subjects: 115
Study: 9779901

Group type: EXPERIMENTAL
Intervention: Community re‐entry program
Number of subjects: 59

Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 59
Study: 8154016

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular sulfadoxine-pyrimethamine
Number of subjects: 0
Study: 3236376

Group type: EXPERIMENTAL
Intervention: Smoking videotape
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control videotape
Number of subjects: 77
Study: 28803880

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU bolus followed by 4000 IU daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 63
Study: 26857762

Group type: EXPERIMENTAL
Intervention: Kernel bread (KB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control bread (CB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both breads (CB and KB)
Number of subjects: 10
Study: 25055933

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 μg every 4 h, maximum of 3 doses)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Intracervical dinoprostone (0.5 mg every 2 h, maximum of 2 doses)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 188

Group type: COMPARATOR
Intervention: Sublingual misoprostol and intracervical dinoprostone
Number of subjects: 188

Group type: COMPARATOR
Intervention: Intracervical dinoprostone
Number of subjects: 188
Study: 23381895

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Monosegmental Fusion
Number of subjects: 27
Study: 22151932

Group type: EXPERIMENTAL
Intervention: Lignin peroxidase cream (LIP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 2% hydroquinone cream
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 19187507

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 55
Study: 16720126

Group type: EXPERIMENTAL
Intervention: Stages of Change education approach
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual care education approach
Number of subjects: 141
Study: 15289368

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU daily
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3706
Study: 16206671

Group type: EXPERIMENTAL
Intervention: Hydrotalcite 1.0 g four times daily for 6 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily for the first 2 weeks and 20 mg once daily for the following 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hydrotalcite
Number of subjects: 45

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 45
Study: 9738364

Group type: EXPERIMENTAL
Intervention: Ibuprofen L-arginine 400 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Naproxen 550 mg
Number of subjects: 70
Study: 7834140

Group type: EXPERIMENTAL
Intervention: Community psychiatric nurse (CPN) care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 0
Study: 2468894

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Potassium (KCl, 20 mEq three times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Calcium (Ca, 500 mg twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Digoxin (sodium‐potassium‐dependent ATPase inhibition)
Number of subjects: 14
Study: 31826706

Group type: EXPERIMENTAL
Intervention: Pure lists condition (six-word lists composed of words belonging to the same valence)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mixed lists condition (six-word lists composed of embedded neutral and emotional words)
Number of subjects: 88
Study: 31332565

Group type: EXPERIMENTAL
Intervention: 30% perfusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60% perfusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100% perfusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histopathological assessment
Number of subjects: 20
Study: 30239887

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDC) - mean initial dose 100 mg/m2
Number of subjects: 2901

Group type: COMPARATOR
Intervention: Low-dose cisplatin (LDC) - mean initial dose 40 mg/m2
Number of subjects: 2901
Study: 28407271

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 144
Study: 25907125

Group type: COMPARATOR
Intervention: Fried food consumption <1 per week
Number of subjects: 15362

Group type: EXPERIMENTAL
Intervention: Fried food consumption 1 to 3 times per week
Number of subjects: 15362

Group type: EXPERIMENTAL
Intervention: Fried food consumption 4 to 6 times per week
Number of subjects: 15362

Group type: EXPERIMENTAL
Intervention: Fried food consumption 7 or more times per week
Number of subjects: 15362
Study: 23891544

Group type: EXPERIMENTAL
Intervention: Educational intervention (10-min lecture with supplementary materials)
Number of subjects: 203
Study: 21665059

Group type: EXPERIMENTAL
Intervention: Support-person intervention (written materials plus three weekly telephone sessions lasting 10-30 minutes each)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Support-person intervention
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group (written materials)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 534
Study: 19183504

Group type: EXPERIMENTAL
Intervention: Health and nutrition education intervention (two two-hour prenatal education sessions and four postpartum counseling visits)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Health and nutrition education intervention
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual health care during pregnancy and postpartum period (Control)
Number of subjects: 302
Study: 16759587

Group type: EXPERIMENTAL
Intervention: Self-measurement of capillary blood glucose (SMBG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diet treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mathematical model for SMBG efficacy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 100
Study: 15320990

Group type: EXPERIMENTAL
Intervention: Combination of rev, tat, and nef intramuscularly at weeks 0, 4, and 16 at increasing doses (300, 900, and 1800 micrograms DNA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of rev, tat, and nef intramuscularly
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of rev, tat, and nef in increasing doses
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients with comparable CD4 levels
Number of subjects: 15
Study: 11131953

Group type: EXPERIMENTAL
Intervention: Expert knowledge about behavioral psychology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naive subjects
Number of subjects: 0
Study: 9330391

Group type: EXPERIMENTAL
Intervention: Japanese herbal medicine (Juzentaihotou or Hotyuekkitou)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (isolation only)
Number of subjects: 0
Study: 1588377

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 3878905

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 treatment for a mean of 16.8 ± 6.4 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 42
Study: 31737366

Group type: EXPERIMENTAL
Intervention: Magnetic endotracheal intubation (METI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic endotracheal intubation (CETI)
Number of subjects: 0
Study: 30365136

Group type: EXPERIMENTAL
Intervention: Simulated spinal manipulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Simulated spinal mobilization
Number of subjects: 12
Study: 25663254

Group type: EXPERIMENTAL
Intervention: VivaSight DLT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional DLT
Number of subjects: 40
Study: 24826396

Group type: EXPERIMENTAL
Intervention: Novel ALA (5-aminolevulinic acid) treatment, 2 treatments 2 weeks apart
Number of subjects: 64

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 64
Study: 22938944

Group type: EXPERIMENTAL
Intervention: Angioplasty alone
Number of subjects: 63
Study: 19390339

Group type: EXPERIMENTAL
Intervention: Health Buddy telehealth communication device
Number of subjects: 13
Study: 17465666

Group type: EXPERIMENTAL
Intervention: BAC-composite with 0.25% BAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAC-composite with 0.75% BAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAC-composite with 1.25% BAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAC-composite with 1.75% BAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAC-composite with 2.5% BAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAC-composite with 5% BAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control composite (no BAC)
Number of subjects: 0
Study: 16081585

Group type: EXPERIMENTAL
Intervention: Montelukast (oral, 10 mg/day) combined with inhaled Budesonide (400 microg/bid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Budesonide (400 microg/bid)
Number of subjects: 40
Study: 12069111

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy based on idebenone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 plus Vitamin E administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9578859

Group type: EXPERIMENTAL
Intervention: Usual breast screening invitation accompanied by a self administered questionnaire
Number of subjects: 6400

Group type: COMPARATOR
Intervention: Usual breast screening invitation alone
Number of subjects: 6400
Study: 10560070

Group type: EXPERIMENTAL
Intervention: Water volumetry
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Figure of eight method
Number of subjects: 29
Study: 1804010

Group type: EXPERIMENTAL
Intervention: Cefepime (2.0 g intravenously twice daily for 4 to 28 days)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ceftazidime (2.0 g every 8 h)
Number of subjects: 79
Study: 6228347

Group type: EXPERIMENTAL
Intervention: Intranasal ipratropium
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31496381

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB) with 10 ml of 0.5% bupivacaine and 10 ml of 2% lidocaine before ESWL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 29087444

Group type: EXPERIMENTAL
Intervention: Intraoperative maneuvers applied for the duration of the entire surgical procedure (group 2)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative measures taken (group 3)
Number of subjects: 122

Group type: COMPARATOR
Intervention: No protective measures taken (group 1)
Number of subjects: 122
Study: 26444149

Group type: EXPERIMENTAL
Intervention: 0.3 μg.kg(‐1) dexmedetomidine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 mg.kg(‐1) propofol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 100
Study: 24857264

Group type: EXPERIMENTAL
Intervention: High-frequency (10 Hz) rTMS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study: 22337531

Group type: EXPERIMENTAL
Intervention: Active TENS (n=117)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Sham TENS (n=119)
Number of subjects: 236
Study: 20516229

Group type: EXPERIMENTAL
Intervention: Dual-task condition with spatially incompatible stimulus‐response mapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task conditions (saccade or manual response)
Number of subjects: 0
Study: 18937112

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif 44 microg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 16
Study: 15794869

Group type: EXPERIMENTAL
Intervention: Oral chlorambucil at a dose of 8 mg/m² (6 mg/m² for those > 75 years of age) for 10 days every 28 days to a maximum of 12 cycles
Number of subjects: 143

Group type: COMPARATOR
Intervention: Oral or intravenous (I.V.) fludarabine at a dose of 40 mg/m² orally or 25 mg/m² I.V. (30 mg/m² orally or 20 mg/m² I.V. for those > 75 years of age) for 5 days every 28 days to a maximum of 6 cycles
Number of subjects: 143
Study: 12872394

Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation combined with XQLD
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fluticasone inhalation
Number of subjects: 54

Group type: COMPARATOR
Intervention: XQLD
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 54
Study: 10697624

Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus vinblastine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Surgery only (Control)
Number of subjects: 18
Study: 9160568

Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (3, 5, and 7 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2690914

Group type: EXPERIMENTAL
Intervention: Oral fluorouracil 500 mg, methotrexate 25 mg and chlorambucil 10 mg p.o. on day 1 and fluorouracil 500 mg and chlorambucil 10 mg p.o. on day 2 (LMF) every 21 days for eight cycles.
Number of subjects: 574

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 574
Study: 971343

Group type: EXPERIMENTAL
Intervention: Secholex (15 g/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cholestyramine (16 g/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Secholex (9 g/day)
Number of subjects: 46
Study: 30198198

Group type: EXPERIMENTAL
Intervention: Mr. Lonely PSA (portrayed outdoor activity as not normative)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control message (VERB PSA, portrayed outdoor activity as the norm)
Number of subjects: 333
Study: 28533305

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4685

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4685
Study: 25781384

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg IV
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo (normal saline IV)
Number of subjects: 213
Study: 23062733

Group type: EXPERIMENTAL
Intervention: Frozen-thawed embryo transfers
Number of subjects: 186

Group type: COMPARATOR
Intervention: Fresh embryo transfers
Number of subjects: 186
Study: 21139446

Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention program (DVD, healthcare booklet, support groups, medical follow-ups)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional health education (control group)
Number of subjects: 60
Study: 18160498

Group type: EXPERIMENTAL
Intervention: Total knee replacement with patellar resurfacing
Number of subjects: 142

Group type: COMPARATOR
Intervention: Total knee replacement without patellar resurfacing
Number of subjects: 142
Study: 16365070

Group type: EXPERIMENTAL
Intervention: Fortified wheat bread
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fortified rye bread
Number of subjects: 41

Group type: COMPARATOR
Intervention: Regular wheat bread (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Regular wheat bread and cholecalciferol supplement (vitamin D control)
Number of subjects: 41
Study: 15490769

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10827226

Group type: EXPERIMENTAL
Intervention: MARS treatment in addition to hemodiafiltration (HDF) and standard medical therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard treatment (HDF and standard medical treatment alone)
Number of subjects: 13
Study: 8770960

Group type: EXPERIMENTAL
Intervention: Supraphysiologic dose B-vitamin supplementation (15 mg folic acid/day, 100 mg B-6/day, 1 mg B-12/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment (1 mg folic acid, 10 mg B-6, 12 micrograms B-12)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Supraphysiologic dose B-vitamin supplementation
Number of subjects: 27
Study: 1608903

Group type: EXPERIMENTAL
Intervention: 75 ml of alcohol (94%) in 75 ml of orange juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: 150 ml of orange juice
Number of subjects: 10
Study: 3885701

Group type: COMPARATOR
Intervention: 100 mg chlorthalidone
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 50 mg chlorthalidone
Number of subjects: 140
Study: 28393552

Group type: EXPERIMENTAL
Intervention: Concern about falling outdoors
Number of subjects: 120